ALKAZAR Ph 3 Trial of Neladalkib for Patients with TKI-naïve ALK-positive NSCLC initiated
“Neladalkib is rationally designed with the goal of addressing the combined medical needs of treating key drivers of disease progression such as brain metastases and treatment-emergent resistance mutations, while also offering a generally safe and well-tolerated safety profile supportive of long-term treatment,” said Darlene Noci, A.L.M., Chief Development Officer at Nuvalent. “We have been encouraged by neladalkib’s clinical profile to date, which we believe not only supports its potential to address clear medical needs for TKI pre-treated patients with advanced ALK-positive NSCLC, but also to translate to deep, durable responses for patients in the front-line setting. The initiation of the registration-directed ALKAZAR study enables us to explore this potential by comparing neladalkib to a front-line standard of care in a randomized, controlled clinical trial setting, and advances us towards our ultimate goal of bringing neladalkib to all patients with advanced ALK-positive NSCLC.”
Share:
More News
Taiho Oncology, Inc. completed a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for zipalertinib in combination with platinum-based chemotherapy for the treatment of patients with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20
“This collaboration reflects our conviction that atebimetinib has the potential to become an essential backbone therapy in a broad range of combinations across MAPK-driven cancers,” said Ben Zeskind, Immuneering CEO and co-founder. “Atebimetinib’s unique tolerability profile and broad activity make it well suited to combine with a wide range of
“These final updated results provide continued evidence of the potential for γδ T cell therapies to drive activity and improve outcomes for patients,” said William Ho, CEO and co-founder of IN8bio. “The clinical outcomes and observed activity are supported by our correlative analysis, including histopathology, demonstrating the expansion and persistence
“Patients with RAS-mutated mCRC have no first-line therapies specifically approved for their disease, and Fast Track designation reflects the potential of onvansertib to address this serious unmet need,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. “Our randomized Phase 2 data give us confidence that onvansertib